Literature DB >> 30252726

YWHAE-NUTM2A/B Translocated High-grade Endometrial Stromal Sarcoma Commonly Expresses CD56 and CD99.

W Glenn McCluggage1, Cheng-Han Lee.   

Abstract

YWHAE-NUTM2A/B translocated high-grade endometrial stromal sarcoma is an uncommon and clinically aggressive uterine mesenchymal neoplasm which is sometimes associated with a low-grade fibromyxoid component. Although the diagnosis is confirmed using molecular techniques, it is possible to make the diagnosis based on the characteristic morphology and the immunophenotype; the latter typically includes diffuse positive staining of the high-grade component with cyclin D1 and CD117 and negative staining with CD10 and hormone receptors. Especially in a small biopsy specimen, in cases without a low-grade component or when presenting with extrauterine disease, the differential diagnosis may be wide and potentially include "small round cell tumors" such as a high-grade neuroendocrine carcinoma and a tumor in the Ewing family. In this study, we report consistent CD56 and CD99 immunoreactivity in YWHAE-NUTM2A/B translocated high-grade endometrial stromal sarcoma. We stained 20 of these neoplasms (10 molecularly confirmed and 10 where diagnosis was based on the morphology and immunophenotype) with CD56 and CD99; in one case, CD56 staining was not performed. Nineteen of 19 (100%) and 17 of 20 (85%) were positive with CD56 and CD99, respectively. Staining was usually diffuse with membranous and cytoplasmic immunoreactivity. Pathologists should be aware that YWHAE-NUTM2A/B translocated high-grade endometrial stromal sarcoma is commonly positive with CD56 and CD99; as well as potentially assisting in diagnosis, positivity with these markers may also result in consideration of other neoplasms in the differential diagnosis.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30252726     DOI: 10.1097/PGP.0000000000000554

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  4 in total

Review 1.  [Mesenchymal and mixed uterine tumors : Current overview and practical aspects].

Authors:  S F Lax
Journal:  Pathologe       Date:  2019-02       Impact factor: 1.011

2.  Targeted RNA expression profiling identifies high-grade endometrial stromal sarcoma as a clinically relevant molecular subtype of uterine sarcoma.

Authors:  Amir Momeni-Boroujeni; Nissreen Mohammad; Robert Wolber; Stephen Yip; Martin Köbel; Brendan C Dickson; Martee L Hensley; Mario M Leitao; Cristina R Antonescu; Ryma Benayed; Marc Ladanyi; Cheng-Han Lee; Sarah Chiang
Journal:  Mod Pathol       Date:  2020-10-19       Impact factor: 7.842

Review 3.  Recurrent uterine tumors resembling ovarian sex-cord tumors with the growth regulation by estrogen in breast cancer 1-nuclear receptor coactivator 2 fusion gene: a case report and literature review.

Authors:  Bin Chang; Qianming Bai; Lin Liang; Huijuan Ge; Qianlan Yao
Journal:  Diagn Pathol       Date:  2020-09-14       Impact factor: 2.644

Review 4.  Update on Endometrial Stromal Tumours of the Uterus.

Authors:  Iolia Akaev; Chit Cheng Yeoh; Siavash Rahimi
Journal:  Diagnostics (Basel)       Date:  2021-03-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.